Back to Search Start Over

Prionoids in amyotrophic lateral sclerosis

Authors :
Philippe Gosset
William Camu
Cedric Raoul
Alexandre Mezghrani
Raoul, Cédric
Institut des Neurosciences de Montpellier (INM)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
CHU Montpellier
Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Kazan Federal University (KFU)
Source :
Brain Communications, Brain Communications, Oxford University Press on behalf of the Guarantors of Brain, 2022, 4 (3), pp.1-16. ⟨10.1093/braincomms/fcac145⟩
Publication Year :
2022
Publisher :
Oxford University Press (OUP), 2022.

Abstract

Amyotrophic lateral sclerosis (ALS) is the third most frequent neurodegenerative disease after Alzheimer’s and Parkinson’s disease. ALS is characterized by the selective and progressive loss of motoneurons in the spinal cord, brainstem and cerebral cortex. Clinical manifestations typically occur in midlife and start with focal muscle weakness, followed by the rapid and progressive wasting of muscles and subsequent paralysis. As with other neurodegenerative diseases, the condition typically begins at an initial point and then spreads along neuroanatomical tracts. This feature of disease progression suggests the spreading of prion-like proteins called prionoids in the affected tissues, which is similar to the spread of prion observed in Creutzfeldt-Jakob disease. Intensive research over the last decade has proposed the ALS-causing gene products Cu/Zn superoxide dismutase 1, TAR DNA-binding protein of 43 kDa, and fused in sarcoma as very plausible prionoids contributing to the spread of the pathology. In this review, we will discuss the molecular and cellular mechanisms leading to the propagation of these prionoids in ALS.

Details

ISSN :
26321297
Volume :
4
Database :
OpenAIRE
Journal :
Brain Communications
Accession number :
edsair.doi.dedup.....5b397fb392a93775f63db1d408431997